Clarity Pharmaceuticals Ltd (CU6) - Net Assets

Latest as of June 2026: AU$186.11 Million AUD ≈ $131.68 Million USD

Based on the latest financial reports, Clarity Pharmaceuticals Ltd (CU6) has net assets worth AU$186.11 Million AUD (≈ $131.68 Million USD) as of June 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (AU$199.06 Million ≈ $140.85 Million USD) and total liabilities (AU$12.96 Million ≈ $9.17 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check CU6 strategic asset allocation to assess the company's strategic physical and investment asset allocation.

Key Net Assets Metrics

Metric	Value
Current Net Assets	AU$186.11 Million
% of Total Assets	93.49%
Annual Growth Rate	77.03%
5-Year Change	101.77%
10-Year Change	N/A
Growth Volatility	152.39

Clarity Pharmaceuticals Ltd - Net Assets Trend (2018–2026)

This chart illustrates how Clarity Pharmaceuticals Ltd's net assets have evolved over time, based on quarterly financial data. For live market cap and overall valuation, see how much is Clarity Pharmaceuticals Ltd worth.

Annual Net Assets for Clarity Pharmaceuticals Ltd (2018–2026)

The table below shows the annual net assets of Clarity Pharmaceuticals Ltd from 2018 to 2026. Also explore CU6 shareholders equity momentum to track the company's year-over-year net asset growth rate.

Year	Net Assets	Change
2026-06-30	AU$186.11 Million ≈ $131.68 Million	+106.26%
2025-06-30	AU$90.23 Million ≈ $63.84 Million	-38.32%
2024-06-30	AU$146.30 Million ≈ $103.51 Million	+111.49%
2023-06-30	AU$69.18 Million ≈ $48.95 Million	-25.00%
2022-06-30	AU$92.24 Million ≈ $65.26 Million	+354.87%
2021-06-30	AU$20.28 Million ≈ $14.35 Million	+148.53%
2020-06-30	AU$8.16 Million ≈ $5.77 Million	-11.57%
2019-06-30	AU$9.23 Million ≈ $6.53 Million	+378.17%
2018-06-30	AU$1.93 Million ≈ $1.37 Million	--

Equity Component Analysis

This analysis shows how different components contribute to Clarity Pharmaceuticals Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

Retained earnings have decreased by 27589386300.0% over the analyzed period, potentially due to dividend distributions or operating losses.

Current Equity Component Breakdown (June 2026)

Component	Amount	Percentage
Common Stock	AU$450.96 Million	242.31%
Other Comprehensive Income	AU$19.27 Million	10.35%
Total Equity	AU$186.11 Million	100.00%

Clarity Pharmaceuticals Ltd Competitors by Market Cap

The table below lists competitors of Clarity Pharmaceuticals Ltd ranked by their market capitalization.

Company	Market Cap
Jiangsu Sihuan Bioengineering Co Ltd SHE:000518	$575.51 Million
Caisse Regionale de Credit Agricole Mutuel Brie Picardie PA:CRBP2	$575.99 Million
Jiangsu Feymer Technology Co Ltd SHG:688350	$575.99 Million
Atlanta Braves Holdings, Inc. Series A Common Stock NASDAQ:BATRA	$576.17 Million
G-Tech Optoelectronics Corp TW:3149	$575.34 Million
Insteel Industries Inc NYSE:IIIN	$575.30 Million
Alpha Hpa Ltd AU:A4N	$575.29 Million
Zhejiang Tiancheng Control Co SHG:603085	$575.27 Million

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Clarity Pharmaceuticals Ltd's equity between the two most recent reporting periods.

Equity Growth Insights

From 2025 to 2026, total equity changed from 90,230,512 to 186,109,256, a change of 95,878,744 (106.3%).
Net loss of 107,143,303 reduced equity.
Other comprehensive income increased equity by 7,928,686.
Other factors increased equity by 195,093,361.

Equity Change Factors (2025 to 2026)

Factor	Impact	Contribution
Net Income	AU$-107.14 Million	-57.57%
Other Comprehensive Income	AU$7.93 Million	+4.26%
Other Changes	AU$195.09 Million	+104.83%
Total Change	AU$-	106.26%

Book Value vs Market Value Analysis

This analysis compares Clarity Pharmaceuticals Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

Current price-to-book ratio: 4.31x
The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
The price-to-book ratio has decreased from 290.30x to 4.31x over the analyzed period, indicating reduced market premium.

Historical Price-to-Book Ratios

Date	Book Value per Share	Market Price	P/B Ratio
2018-06-30	AU$0.01	AU$2.18	x
2019-06-30	AU$0.04	AU$2.18	x
2020-06-30	AU$0.03	AU$2.18	x
2021-06-30	AU$0.08	AU$2.18	x
2022-06-30	AU$0.37	AU$2.18	x
2023-06-30	AU$0.27	AU$2.18	x
2024-06-30	AU$0.54	AU$2.18	x
2025-06-30	AU$0.28	AU$2.18	x
2026-06-30	AU$0.51	AU$2.18	x

Capital Efficiency Dashboard

This dashboard shows how efficiently Clarity Pharmaceuticals Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

Current Return on Equity (ROE): -57.57%
The company may be facing challenges in efficiently utilizing shareholder equity.
DuPont Analysis Breakdown:
• Net Profit Margin: 0.00%
• Asset Turnover: 0.00x
• Equity Multiplier: 1.07x
Recent ROE (-57.57%) is below the historical average (-53.75%), suggesting potential challenges in capital efficiency.

Historical Capital Efficiency Metrics

Year	Return on Equity	Net Profit Margin	Asset Turnover	Equity Multiplier	Economic Value Added
2018	-89.10%	-69.86%	0.88x	1.44x	AU$-1.91 Million
2019	-39.93%	-139.37%	0.26x	1.12x	AU$-4.61 Million
2020	-85.23%	-249.35%	0.31x	1.12x	AU$-7.77 Million
2021	-50.41%	-319.77%	0.14x	1.12x	AU$-12.25 Million
2022	-25.75%	-367.78%	0.06x	1.08x	AU$-32.98 Million
2023	-35.57%	-251.03%	0.13x	1.11x	AU$-31.52 Million
2024	-28.93%	-367.83%	0.07x	1.06x	AU$-56.95 Million
2025	-71.26%	-679.45%	0.09x	1.12x	AU$-73.32 Million
2026	-57.57%	0.00%	0.00x	1.07x	AU$-125.75 Million

Industry Comparison

This section compares Clarity Pharmaceuticals Ltd's net assets metrics with peer companies in the Biotechnology industry.

Industry Context

Industry: Biotechnology
Average net assets among peers: $7,433,724
Average return on equity (ROE) among peers: -298.39%

Peer Company Comparison

Company	Net Assets	Return on Equity	Debt-to-Equity	Market Cap
Clarity Pharmaceuticals Ltd (CU6)	AU$186.11 Million	-89.10%	0.07x	$575.47 Million
Adalta Ltd (1AD)	$5.38 Million	-112.69%	0.98x	$5.41 Million
Algorae Pharmaceuticals Ltd (1AI)	$3.14 Million	0.00%	0.26x	$12.88 Million
ACRUX Ltd (ACR)	$9.09 Million	-108.18%	0.68x	$2.91 Million
Actinogen Medical Ltd (ACW)	$12.13 Million	-29.97%	0.07x	$130.32 Million
Argenica Therapeutics Ltd (AGN)	$18.40K	-2084.05%	19.53x	$13.63 Million
Arovella Therapeutics Ltd (ALA)	$19.30 Million	-17.45%	0.18x	$50.46 Million
Anatara Lifesciences Ltd (ANR)	$535.97K	-364.70%	1.14x	$1.57 Million
Alterity Therapeutics Ltd (ATH)	$6.93 Million	-92.79%	0.30x	$108.75 Million
Amplia Therapeutics Ltd (ATX)	$11.42 Million	-39.44%	0.30x	$45.40 Million
Avecho Biotechnology Ltd (AVE)	$6.40 Million	-134.59%	0.29x	$54.68 Million

About Clarity Pharmaceuticals Ltd

AU:CU6 Australia Biotechnology

Market Cap

$575.47 Million

AU$813.32 Million AUD

Market Cap Rank

#11631 Global

#297 in Australia

Share Price

AU$2.18

Change (1 day)

+3.81%

52-Week Range

AU$1.82 - AU$5.70

All Time High

AU$8.79